Stock Analysis
- Hong Kong
- /
- Healthtech
- /
- SEHK:2251
Insiders continue to buy Beijing Airdoc Technology Co., Ltd. (HKG:2251) and now own 30% shares
Key Insights
- Beijing Airdoc Technology's significant insider ownership suggests inherent interests in company's expansion
- A total of 6 investors have a majority stake in the company with 53% ownership
- Insiders have been buying lately
If you want to know who really controls Beijing Airdoc Technology Co., Ltd. (HKG:2251), then you'll have to look at the makeup of its share registry. With 30% stake, individual insiders possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
Having purchased shares recently, insiders must be glad after market cap hit HK$1.2b last week.
Let's take a closer look to see what the different types of shareholders can tell us about Beijing Airdoc Technology.
See our latest analysis for Beijing Airdoc Technology
What Does The Institutional Ownership Tell Us About Beijing Airdoc Technology?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
We can see that Beijing Airdoc Technology does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Beijing Airdoc Technology, (below). Of course, keep in mind that there are other factors to consider, too.
Beijing Airdoc Technology is not owned by hedge funds. The company's CEO Dalei Zhang is the largest shareholder with 18% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 10.0% and 9.5%, of the shares outstanding, respectively.
We did some more digging and found that 6 of the top shareholders account for roughly 53% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. While there is some analyst coverage, the company is probably not widely covered. So it could gain more attention, down the track.
Insider Ownership Of Beijing Airdoc Technology
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
Our most recent data indicates that insiders own a reasonable proportion of Beijing Airdoc Technology Co., Ltd.. It has a market capitalization of just HK$1.2b, and insiders have HK$363m worth of shares in their own names. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently.
General Public Ownership
The general public, who are usually individual investors, hold a 26% stake in Beijing Airdoc Technology. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
Private Company Ownership
It seems that Private Companies own 23%, of the Beijing Airdoc Technology stock. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.
Next Steps:
While it is well worth considering the different groups that own a company, there are other factors that are even more important.
I always like to check for a history of revenue growth. You can too, by accessing this free chart of historic revenue and earnings in this detailed graph.
If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Valuation is complex, but we're here to simplify it.
Discover if Beijing Airdoc Technology might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SEHK:2251
Beijing Airdoc Technology
Provides artificial intelligence (AI) empowered retina-based early detection, diagnosis, and health risk assessment solutions for medical institutions, consumer healthcare environments, and eye health management settings in Mainland China and internationally.